T-cell vaccination for autoimmune diseases: Immunologic lessons and clinical experience in multiple sclerosis

Expert Review of Vaccines

Volumn 1, Issue 3, 2002, Pages 285-292

  Zhang, Jingwu ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Multiple sclerosis; Myelin reactive T cells; T cells vaccination

Indexed keywords

DNA VACCINE; GLATIRAMER; MYELIN; MYELIN BASIC PROTEIN; VACCINE;

AUTOIMMUNE DISEASE; CELL POPULATION; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREGULATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; MYELIN SHEATH; T-LYMPHOCYTES; VACCINATION;

EID: 0037509927     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.3.285     Document Type: Review

References (39)

1. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant MBP epitope in multiple sclerosis. Nature 346, 183-187 (1990).
2. Steinman L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 85, 299-302 (1996).
3. Zhang J, Medaer R, Hashim G, Ying C, van den Berg-Loonen E, Raus J. Myelin basic protein-specific T-lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity and cytotoxicity. Ann. Neurol. 32, 330-338 (1992).
4. Hafler D. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J. Clin. Invest. 104, 527-529 (1999).
5. Soldan SS, Berti R, Salem N et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat. Med. 3, 1394-1397 (1997).
6. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Killian JM, Zhang JZ. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. J. Virol. 76, 6147-6154 (2002).
7. Wucherpfennig K, Strominger J. Molecular mimicry in T-cell-mediated autoimmunity: viral peptides activate human T-cell clones specific for myelin basic protein. Cell 80, 695-705 (1995).
8. Hemmer B, Fleckenstein BT, Vergelli M et al. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T-cell clone. J. Exp. Med. 9, 1651-1659 (1997).
9. Kozovska M, Zang YC, Aebischer I et al. T-cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: structural requirements and clinical implications. Eur. J. Immunol. 6, 1894-901 (1998).
10. Zamvil S, Ndson P, Trotter J et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317, 355-358 (1985).
11. Allegretta M, Nicklas JA, Sriam S, Albertini RJ. T-cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247, 718-721 (1990).
12. Chou YK, Bourdette DN, Offner H et al. Frequency of T-cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J. Neuroimmunol. 38, 105-114 (1992).
13. Zhang J, Markovic S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin-2-responsive T-cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179, 973-984 (1994).
14. Tejada-Simon MV, Yang D, Zang Y, Rivera V, Zhang J. T-cell reactivity to myelin antigens and their structural and functional properties at different clinical stages of multiple sclerosis. Int. Immunol. 12, 1641-1650 (2000).
15. Madsen LS, Andersson EC, Jansson L et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 23, 343-347 (1999).
16. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 292, 60-61 (1981). The first demonstration of T-cell vaccination in an autoimmune animal model.
17. Lider O, Karin N, Shinitzky M, Cohen IR. Therapeutic vaccination against adjuvant arthritis using autoimmune T-cells treated with hydrostatic pressure. Proc. Natl Acad. Sci. USA 84, 4577-4580 (1987).
18. Beraud E, Kotake S, Caspi RR et al. Control of experimental autoimmune uveoretinitis by low dose T-cell vaccination. Cell. Immunol. 140, 112-122 (1992).
19. Hafler D, Cohen IR, Benjamine D, Weiner HL. T-cell vaccination in multiple sclerosis: a preliminary report. Clin. Immunol. Immunopath. 62, 307-312 (1992).
20. Zhang J, Medaer R, Srinissen P, Hailer DA, Raus J. MHC restricted clonotypic depletion of human myelin basic protein-reactive T-cells by T-cell vaccination. Science 261, 1451-1454 (1993). First T-cell vaccination clinical trial in MS patients using myelin-reactive T-cell clones. The study demonstrated clonal depletion of circulating myelin-reactive T-cells and CD8+ cytolytic anti-idiotypic T-cell responses induced by T-cell vaccination.
21. Zhang J, Raus J. T-cell vaccination in human autoimmune diseases: from laboratory to clinic. Hum. Immunol. 38, 87-96 (1993).
22. Zhang J, Vandevyver C, Stinissen P, Raus J. In vivo clonotypic regulation of human myelin basic protein-reactive T-cells by T-cell vaccination. J. Immunol 155, 5808-5877 (1995).
23. Medaer R, Stinissen P, Truyen L, Raus J, Zhang J. Depletion of myelin basic protein autoreactive T-cells by T-cell vaccination: Clinical trial in multiple sclerosis. Lancet 346, 807-808 (1995). Summarizes the clinical results for an independent clinical trial in MS patients.
24. Correale J, Lund B, McMillan M, Ko DY, McCarthy K, Weiner LP. T-cell vaccination in secondary progressive multiple sclerosis. J. Neuroimmunol 107, 130-139 (2000). Summarizes the clinical results for an independent clinical trial in MS patients.
25. Zhang JZ, Rivera VM, Tejada-Simon MV et al. T-cell vaccination in multiple sclerosis: results of a preliminary study. J. Neurol 249, 212-218 (2002). Summarizes the clinical results for an independent clinical trial in MS patients.
26. Zang Y, Hong J, Rivera V, Killian J, Zhang J. Preferential recognition of hypervariable region sequence by anti-idiotypic T-cells induced by T-cell vaccination in patients with multiple sclerosis. J. Immunol 164, 4011-4017 (2000). Further evidence that CD8+ cytolytic anti-idiotypic T-cells induced by T-cell vaccination recognize the T-cell receptors and CDR3 region sequences of immunizing myelin-reactive T-cell clones in MS patients.
27. Saruham-Direskeneli G, Weber F, Meinl E et al. Human T-cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T-cell receptor β chain from a myelin basic protein-specific T-cell clone. Eur. J. Immunol 23, 530-540 (1993).
28. Hong J, Zang Y, Rivera V, Zhang J. Reactivity and regulatory properties of anti-idiotypic antibodies induced by T-cell vaccination in patients with multiple sclerosis. J. Immunol 165, 6858-6864 (2000).
29. Zang Y, Hong J, Tejada-Simon M et al. Th2 immune regulation induced by T-cell vacination in patients with multiple sclerosis. Eur. Immunol. 30, 908-913 (2000).
30. Saeki Y, Mima T, Sakoda S et al. Transfer of multiple sclerosis into severe combined immunodeficiency mice by mononuclear cells from cerebrospinal fluid of the patients. Proc. Natl Acad. Sci. USA 89, 6157-6161 (1992).
31. Fujimura H, Nakatsuji Y, Sakoda S et al. Demyelination in severe combined immtmodeficient mice by intracisternal injection of cerebrospinal fluid cells from patients with multiple sclerosis: neuropathological investigation. Acta Neuropathol. (Berl) 93, 567-578 (1997).
32. Hermans G, Medaer R, Raus J, Stinissen P. Myelin reactive T-cells after T-cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. J. Neuroimmunol. 102, 79-84 (2000).
33. Tuohy VK, Yu M, Yin L, Kawczak JA, Kinkel RP. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 189, 1033-1042 (1999).
34. Vandenbark, AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341, 541-544, (1989).
35. Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW. Vaccination against experimental encephalomyelitis with T-cell receptor peptides. Science 246, 668-670 (1989).
36. Kumar V, Sercarz E. The involvement of T-cell receptor peptide-specific regulatory CD4+ T-cells in recovery from antigen-induced autoimmune disease. J. Exp. Med. 178, 909-916 (1993).
37. Vandenbark AA, Chou YK, Witham R et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat. Med. 10, 1109-1115 (1996). Immunoregulatory and preliminary clinical indications of peptide-based vaccination using T-cell receptor CDR2 peptides in patients with MS.
38. Hong J, Zang Y, Tejada-Simon M et al. A common TCR sequence motif shared by myelin basic protein-reactive T-cells in patients with multiple sclerosis. J. Immunol. 163, 3530-3538 (1999).
39. Kumar V, Sercarz E, Zhang J, Cohen IR. T cell vaccination: From basics to the clinic. Trends Immunol. 22, 539-540 (2001).